This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Previously Presented): A compound of formula I

$$R^1 \xrightarrow{E} X^{R^2} X - Y - T$$
 $D - G O$ 

in which

R<sup>1</sup> is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, -OCOR<sup>3</sup>, NHCOA or NHSO<sub>2</sub>A,

R<sup>2</sup> is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R<sup>1</sup> and R<sup>2</sup> together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

 $R^3$  is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

D is phenyl, pyridyl or thienyl, which in each case is monosubstituted or disubstituted by Hal,

G is  $(CH_2)_n$  or  $(CH_2)_nNH$ -,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl

		oxygen,
	A	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 $\rm H$
		atoms are each optionally replaced by F,
	Hal	is F, Cl, Br or I, and
	n	is 0, 1 or 2;
or a ph	narmace	utically usable salt, or stereoisomer thereof, including mixtures thereof in all
ratios.		
	2.	(Cancelled):
	3.	(Cancelled):
	4.	(Cancelled):
	5.	(Cancelled):
	6.	(Cancelled):
	7.	(Cancelled):
	8.	(Cancelled):
	9.	(Cancelled):
	10.	(Cancelled):
	11.	(Cancelled):
	12.	(Cancelled):

(Cancelled):

13.

14.	(Cancelled):
15.	(Cancelled):
16.	(Cancelled):
17.	(Cancelled):
18.	(Cancelled):
19.	(Cancelled):
20.	(Cancelled):
21.	(Cancelled):
22.	(Cancelled):
23.	(Previously Presented): A compound according to Claim 1, wherein said
compound	is selected from:
1-N	I-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2
dicarboxar	nide,
	I-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-
	e-1,2-dicarboxamide,
	I-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-
	e-1,2-dicarboxamide,
	N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-
	:-1,2-dicarboxamide,
	N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-
(R)-pyrroli	dine-1,2-dicarboxamide,

- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-piperidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-oxazolidine-3, 4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-thiazolidine-3, 4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-1,1-dioxo-1\lambda^6-thiazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo- $1\lambda^6$ -thiazolidine-3,4-dicarboxamide,
  - N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-

carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(5-chloropyridin-2-yl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-4, 4-dimethoxypyrrolidine-1, 2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,$ 

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,\\$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl isobutyrate,
- (3R, 5R) 1 (4-chlorophenylcarbamoyl) 5 [4 (3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl propionate,
- $(3R, 5R) \hbox{-} 1 \hbox{-} (4 \hbox{-} chlorophenyl carbamoyl) \hbox{-} 5 \hbox{-} [4 \hbox{-} (3 \hbox{-} oxomorpholin-4 \hbox{-} yl) \hbox{-} phenyl carbamoyl] pyrrolidin-3 \hbox{-} yl acetate,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-2, 2-dimethyl-4, 5-dicarboxamide,$
- $4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-2, 2-dimethyl-4, 5-dicarboxamide,$

- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1-BOC-piperazine-1,2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperazine-1, 2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-oxazinane-3, 4-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- $\label{eq:continuous} 6-N-[(4-chlorophenyl)]-7-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-4-oxopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1, 2-dicarboxamide,$
- $N-(4-chlorophenyl)-(R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(2R,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(2R,4S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,\\$
- $N-(4-chlorophenyl)-(2S,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

- 9 -

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-bromophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-3-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1, 3-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-3-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1,3-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 


1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 24. (Cancelled):
- 25. (Cancelled):
- 26. (Previously Presented): A process for the preparation of compounds according to claim 1, said process comprising
- a) for the preparation of compounds of the formula I in which  $\,W$  is  $\,N$  and  $\,G\,$  is  $\,NH,\,$

a compound of formula II



in which

R<sup>1</sup>, R<sup>2</sup>, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula III


in which

D is as defined in Claim 1,

or

b) for the preparation of compounds of formula I in which W is N,

a compound of formula II



in which

R<sup>1</sup>, R<sup>2</sup>, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula VI


D-G-CO-L VI

in which	1	- 1	٠	•			٠
	h	C	11	h	337	n	1


D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

	and/or	
	a base	or acid of the formula I is converted into one of its salts.
	27.	(Cancelled):
	28.	(Cancelled):
	29.	(Previously Presented): A medicament composition comprising at least one
compo		cording to claim 1 and one or more excipients and/or adjuvants.
compo		crowing to craim 1 and one of more entriprents and of adjustants.
	30.	(Previously Presented): A medicament composition comprising at least one
2011110		
compo	und acc	cording to claim 1 and at least one further medicament active ingredient.
	2.1	
	31.	(Cancelled):
	22	
	32.	(Previously Presented): A kit comprising separate packs of:
	(a)	an effective amount of a compound according to claim 1,
	and	
	(b)	an effective amount of a further medicament active ingredient.
	33.	(Cancelled):
	34.	(Cancelled):
	35.	(Cancelled):
	36.	(Cancelled):


- 37. (Cancelled):
- 38. (Cancelled):
- 39. (Cancelled):
- 40. (Previously Presented): A medicament composition according to Claim 30, wherein said at least one compound is 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios, and said at least one further medicament active ingredient is aspirin.
  - 41. (Cancelled):
  - 42. (Previously Presented): A compound according to claim 1, wherein




- G is -NH-, and
- X is CONH.
- 43. (Previously Presented): A compound according to claim 1, wherein R<sup>1</sup> is H, =O, COOA, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino.
- 44. (Previously Presented): A compound according to claim 1, wherein R<sup>2</sup> is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
  - 45. (Previously Presented): A compound according to claim 1, wherein R<sup>3</sup> is H.
  - 46. (Previously Presented): A compound according to claim 1, wherein




47. (Previously Presented): A compound according to claim 1, wherein




48. (Previously Presented): A compound according to claim 1, wherein




49. (Previously Presented): A compound according to claim 1, wherein




50. (Previously Presented): A compound according to claim 1, wherein



51. (Previously Presented): A compound according to claim 1, wherein



52. (Previously Presented): A compound according to claim 1, wherein



- 53. (Previously Presented): A compound according to claim 1, wherein E is piperazine-1,4-diyl.
- 54. (Previously Presented): A compound according to claim 1, wherein E is tetrahydrofuran-3,4-diyl.
- 55. (Previously Presented): A compound according to claim 1, wherein E is or azetidine-1,2-diyl.
- 56. (Previously Presented): A compound according to claim 1, wherein D is phenyl which is monosubstituted or disubstituted by Hal.
- 57. (Previously Presented): A compound according to claim 1, wherein D is pyridyl which is monosubstituted or disubstituted by Hal.
- 58. (Previously Presented): A compound according to claim 1, wherein D is thienyl which is monosubstituted or disubstituted by Hal.
- 59. (Previously Presented): A compound according to claim 1, wherein G is  $(CH_2)_n$ .
- 60. (Previously Presented): A compound according to claim 1, wherein G is  $(CH_2)_nNH_-$ .
  - 61. (Cancelled):

62	(Cancelled):
63	(Cancelled):
64	(Cancelled):
65	(Cancelled):
66	(Cancelled):
67	(Cancelled):
68	(Cancelled):
69	(Cancelled):
70 R <sup>1</sup>	(Previously Presented): A compound according to claim 1, wherein is H, =O, COOA, OH, OA, NH <sub>2</sub> , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N <sub>3</sub> ,
	nyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino;
• •	is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;
	s phenyl which is monosubstituted or disubstituted by Cl, pyridyl which is
	tituted or disubstituted by Cl, or thienyl which is monosubstituted or disubstituted
by Cl;	

G is  $(CH_2)_n$ ; and n is 0.

71. (New): A compound of formula I

in which

R<sup>1</sup> is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, -OCOR<sup>3</sup>, NHCOA or NHSO<sub>2</sub>A,

R<sup>2</sup> is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

 $R^1$  and  $R^2$  together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

 $R^3$  is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

D is phenyl, pyridyl or thienyl, which in each case is monosubstituted or disubstituted by Hal,

G is  $(CH_2)_n$  or  $(CH_2)_nNH$ -,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

or a pharmaceutically usable salt thereof.